The Phase 3 ALKIVIA study by argenx demonstrated that efgartigimod significantly improved symptoms in patients with autoimmune myositis, including immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM). The study met its primary and key secondary endpoints, showing rapid and sustained improvements in muscle strength, disease activity, and skin symptoms, with a favorable safety profile. These results support argenx's plan to submit for FDA approval of efgartigimod as the first targeted treatment for IMNM by the end of 2026. This marks a significant advancement for a disease with no approved therapies, offering hope for better management of autoimmune myositis.
The Phase 3 ALKIVIA study by argenx on autoimmune myositis is the subject, with Pluang providing health-sector market context as of Nov 07, 2026 22:21 WIB. On that day, 88 of 150 priced health-sector US stocks rose while 62 fell. Notable movers included ELAN at USD 25.74 with an 8.75% increase, ERAS at USD 14.41 up 8.59%, and RVMD at USD 192.28 rising 8.24%.
Johnson & Johnson announced new patient data from the Phase 2 DAHLIAS study showing nipocalimab significantly improves mouth dryness, the most impactful symptom for Sjögren's disease patients. The drug also increased saliva production by 50% in more ...
Johnson & Johnson announced positive Phase 3 trial results for ICOTYDE (icotrokinra), an oral peptide targeting IL-23R, in treating biologic-naïve adults with active psoriatic arthritis. At 16 weeks, 58% of patients achieved ACR20 response versus 41%...
Uber Technologies is falling behind competitors Waymo and Tesla in the U.S. robotaxi market, projecting only 2,000 robotaxis by 2027 compared to Waymo's 20,000 and Tesla's plans for millions. The company's revenue growth is slowing, with Q3 growth un...
Bitcoin's total mining hashrate has rebounded above one zettahash over the past week, signaling renewed strength in the network's mining competition. This recovery suggests that recent exits by some mining companies do not indicate an overall decline...
Ether (ETH) experienced $11.59 million in long position liquidations within an hour ending at 6:10 p.m. ET on Nov. 5, part of a total $13.16 million liquidated across Binance, Bybit, and OKX exchanges. The price of ETH fell from $2,236 to $2,208, a 1...
